Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 5, 2003

View Archived Issues

A role for IL-15 in the pathogenesis of psoriasis

New NHE inhibitors and their use reported by Aventis team

Protein prenyltransferase inhibitors newly identified at PPD Discovery

Ortho-McNeil scientists discover new androgen receptor modulators

Wyeth claims new agents able to inhibit PEPCK production and lower glucose and insulin levels

Novel sst receptor modulators prepared and tested at ChemBridge

GSK scientists present new beta2-adrenoceptor agonists for use in respiratory disorders

In vitro and in vivo antitumor effects of GW-572016

Bevacizumab plus docetaxel in metastatic breast cancer

Celecoxib supplementation allows more breast-conserving surgery for LABC

Antitumor effects of CCI-779 in breast cancer: final results of a phase II trial

Protein farnesyltransferase inhibitor R-115777 assessed in breast cancer model

Preliminary phase II results reported for vinflunine in metastatic breast cancer

Unique mechanism of action and binding sites for Avanir's anthrax antibodies

Barr begins Seasonale promotion

Barr to acquire Endeavor assets

Phase I study evaluates oral clofarabine in solid tumors

BioSante reviews third-quarter developments

Domantis creates potent dual-action domain antibodies

Orphan drug status for AEOL-10150 for ALS

Isotechnika's immunosuppressive pipeline expands with TKB-662

Kemin identifies molecules with activity against CMV

Lipid Sciences evaluates delipidation technology in nonhuman primate studies

MorphoSys antibodies bind to amyloid plaques in animal model of Alzheimer's disease

Sepracor discontinues development of Soltara

Zorbtive receives FDA approval for short bowel syndrome

Positive results for lead compounds in Theravance/GlaxoSmithKline alliance

Clinical studies of rhThrombin cleared to commence

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...